Court proceedings initiated for immediate market approval of Brixadi™ in the US
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product.
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product. Buvidal is approved for the treatment of opioid dependence in the EU and Australia.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/
Latest news
2022-10-03
Sandberg Development invests in the water innovation company Drupps
In alignment with the group’s investment philosophy, Sandberg Development has invested in the Swedish water innovati…